EFPIA Names Joe Jimenez as New President

Article

EFPIA announced that Joe Jimenez, CEO of Novartis, has been appointed as its new president, following confirmation by the EFPIA Board on December 9. Jimenez will work alongside Dr. Stefan Oschmann, CEO Pharma of Merck KGaA, and Marc de Garidel, Chairman and CEO of Ipsen, who have been appointed as vice-presidents by the Board, also on December 9.

Jimenez previously served as EFPIA vice-president. He was already EFPIA’s president-elect at the time of former EFPIA president Chris Viehbacher’s resignation on October 29, 2014 and due to take over leadership of EFPIA in June 2015. The Board has agreed to extend Joe Jimenez’s appointment until June 2017; this is to be ratified during the EFPIA General Assembly in June 2015.

Source: EFPIA

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content